{"id":"https://openalex.org/W2522643247","doi":"https://doi.org/10.1111/dom.12788","title":"Evaluation of the efficacy, safety and glycaemic effects of evolocumab ( AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome","display_name":"Evaluation of the efficacy, safety and glycaemic effects of evolocumab ( AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome","alternate_titles":[],"publication_year":2016,"publication_date":"2016-10-14","ids":{"openalex":"https://openalex.org/W2522643247","doi":"https://doi.org/10.1111/dom.12788","mag":"2522643247","pmid":"https://pubmed.ncbi.nlm.nih.gov/27619750"},"language":"en","primary_location":{"id":"doi:10.1111/dom.12788","doi":"https://doi.org/10.1111/dom.12788","is_oa":false,"landing_page_url":"https://doi.org/10.1111/dom.12788","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2522643247"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5078515650","display_name":"Dirk Jacobus Blom","orcid":"https://orcid.org/0000-0003-3965-5912","observed_orcids":["https://orcid.org/0000-0003-3965-5912"]},"institutions":[{"id":"https://openalex.org/I157614274","display_name":"University of Cape Town","ror":"https://ror.org/03p74gp79","country_code":"ZA","type":"education","lineage":["https://openalex.org/I157614274"]}],"countries":["ZA"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Dirk J. Blom","raw_affiliation_strings":["Division of Lipidology, Department of Medicine, University of Cape Town, Cape Town, South Africa"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Lipidology, Department of Medicine, University of Cape Town, Cape Town, South Africa","institution_ids":["https://openalex.org/I157614274"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032891959","display_name":"Michael J. Koren","orcid":"https://orcid.org/0000-0001-5023-7178","observed_orcids":["https://orcid.org/0000-0001-5023-7178"]},"institutions":[{"id":"https://openalex.org/I4210135343","display_name":"Jacksonville Center for Clinical Research","ror":"https://ror.org/03ftkmq63","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210135343"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Michael J. Koren","raw_affiliation_strings":["Jacksonville Center for Clinical Research, Jacksonville, Florida"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jacksonville Center for Clinical Research, Jacksonville, Florida","institution_ids":["https://openalex.org/I4210135343"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089409959","display_name":"Eli M. Roth","orcid":"https://orcid.org/0000-0002-3367-5704","observed_orcids":["https://orcid.org/0000-0002-3367-5704"]},"institutions":[{"id":"https://openalex.org/I4210090186","display_name":"Sterling Research Group","ror":"https://ror.org/009prea33","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210090186"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Eli Roth","raw_affiliation_strings":["Sterling Research Group, Cincinnati, Ohio"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sterling Research Group, Cincinnati, Ohio","institution_ids":["https://openalex.org/I4210090186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052274869","display_name":"Maria Laura Monsalvo","orcid":"https://orcid.org/0000-0002-4113-9418","observed_orcids":["https://orcid.org/0000-0002-4113-9418"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Maria Laura Monsalvo","raw_affiliation_strings":["Amgen Inc., Thousand Oaks, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Thousand Oaks, California","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004271735","display_name":"C. Stephen Djedjos","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"C. Stephen Djedjos","raw_affiliation_strings":["Gilead Sciences, Fremont, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences, Fremont, California","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020475314","display_name":"Patric Nelson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800035258","display_name":"Ionis Pharmaceuticals (United States)","ror":"https://ror.org/00t8bew53","country_code":"US","type":"company","lineage":["https://openalex.org/I2800035258"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Patric Nelson","raw_affiliation_strings":["Ionis Pharmaceuticals, San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ionis Pharmaceuticals, San Diego, California","institution_ids":["https://openalex.org/I2800035258"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Mary Elliott","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117596","display_name":"Amgen (United Kingdom)","ror":"https://ror.org/02gvvc992","country_code":"GB","type":"company","lineage":["https://openalex.org/I1320553840","https://openalex.org/I4210117596"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Mary Elliott","raw_affiliation_strings":["Amgen Limited, Cambridge, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Limited, Cambridge, UK","institution_ids":["https://openalex.org/I4210117596"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086317157","display_name":"Scott M. Wasserman","orcid":"https://orcid.org/0000-0003-0634-6021","observed_orcids":["https://orcid.org/0000-0003-0634-6021"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Scott M. Wasserman","raw_affiliation_strings":["Amgen Inc., Thousand Oaks, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Thousand Oaks, California","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052604218","display_name":"Christie Mitchell Ballantyne","orcid":"https://orcid.org/0000-0002-6432-1730","observed_orcids":["https://orcid.org/0000-0002-6432-1730"]},"institutions":[{"id":"https://openalex.org/I1295876152","display_name":"Houston Methodist","ror":"https://ror.org/027zt9171","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1295876152"]},{"id":"https://openalex.org/I181547552","display_name":"Baylor College of Medicine","ror":"https://ror.org/02pttbw34","country_code":"US","type":"education","lineage":["https://openalex.org/I181547552","https://openalex.org/I2801539370"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Christie M. Ballantyne","raw_affiliation_strings":["Baylor College of Medicine, Houston, Texas","Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Baylor College of Medicine, Houston, Texas","institution_ids":["https://openalex.org/I181547552"]},{"raw_affiliation_string":"Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas","institution_ids":["https://openalex.org/I1295876152"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5049740900","display_name":"Rury R. Holman","orcid":"https://orcid.org/0000-0002-1256-874X","observed_orcids":["https://orcid.org/0000-0002-1256-874X"]},"institutions":[{"id":"https://openalex.org/I40120149","display_name":"University of Oxford","ror":"https://ror.org/052gg0110","country_code":"GB","type":"education","lineage":["https://openalex.org/I40120149"]},{"id":"https://openalex.org/I4210129944","display_name":"Oxford Centre for Diabetes, Endocrinology and Metabolism","ror":"https://ror.org/03myafa32","country_code":"GB","type":"facility","lineage":["https://openalex.org/I40120149","https://openalex.org/I4210129944","https://openalex.org/I4210147381"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Rury R. Holman","raw_affiliation_strings":["Diabetes Trials Unit, OCDEM, University of Oxford, Oxford, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Diabetes Trials Unit, OCDEM, University of Oxford, Oxford, UK","institution_ids":["https://openalex.org/I40120149","https://openalex.org/I4210129944"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":11,"corresponding_author_ids":["https://openalex.org/A5078515650"],"corresponding_institution_ids":["https://openalex.org/I157614274"],"apc_list":{"value":5380,"currency":"USD","value_usd":5380},"apc_paid":null,"fwci":7.0078,"has_fulltext":false,"cited_by_count":66,"citation_normalized_percentile":{"value":0.97964823,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":100},"biblio":{"volume":"19","issue":"1","first_page":"98","last_page":"107"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":0.0017000000225380063,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13430","display_name":"Lipid metabolism and disorders","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/evolocumab","display_name":"evolocumab","score":1.0},{"id":"https://openalex.org/keywords/pcsk9-inhibition","display_name":"PCSK9 inhibition","score":0.8970000147819519},{"id":"https://openalex.org/keywords/hypercholesterolemia","display_name":"hypercholesterolemia","score":0.9879999756813049},{"id":"https://openalex.org/keywords/ldl-cholesterol-lowering","display_name":"LDL cholesterol lowering","score":0.640999972820282},{"id":"https://openalex.org/keywords/dysglycemia","display_name":"dysglycemia","score":0.7879999876022339},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9739999771118164},{"id":"https://openalex.org/keywords/impaired-fasting-glucose","display_name":"impaired fasting glucose","score":0.9980000257492065},{"id":"https://openalex.org/keywords/metabolic-syndrome","display_name":"metabolic syndrome","score":0.996999979019165},{"id":"https://openalex.org/keywords/new-onset-diabetes","display_name":"new-onset diabetes","score":0.7400000095367432},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.7559999823570251},{"id":"https://openalex.org/keywords/insulin-resistance","display_name":"insulin resistance","score":0.49000000953674316}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9070550203323364},{"id":"https://openalex.org/C2778114629","wikidata":"https://www.wikidata.org/wiki/Q15623825","display_name":"Evolocumab","level":5,"score":0.6625864505767822},{"id":"https://openalex.org/C2780578515","wikidata":"https://www.wikidata.org/wiki/Q657193","display_name":"Metabolic syndrome","level":3,"score":0.426738440990448},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.39789021015167236},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.33220335841178894},{"id":"https://openalex.org/C62746215","wikidata":"https://www.wikidata.org/wiki/Q14890615","display_name":"Apolipoprotein B","level":3,"score":0.21874874830245972},{"id":"https://openalex.org/C511355011","wikidata":"https://www.wikidata.org/wiki/Q12174","display_name":"Obesity","level":2,"score":0.10948339104652405},{"id":"https://openalex.org/C2778163477","wikidata":"https://www.wikidata.org/wiki/Q43656","display_name":"Cholesterol","level":2,"score":0.0919758677482605},{"id":"https://openalex.org/C2780745583","wikidata":"https://www.wikidata.org/wiki/Q1316030","display_name":"Apolipoprotein A1","level":4,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000924","descriptor_name":"Anticholesteremic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D002096","descriptor_name":"C-Peptide","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006442","descriptor_name":"Glycated Hemoglobin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006937","descriptor_name":"Hypercholesterolemia","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D006937","descriptor_name":"Hypercholesterolemia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006937","descriptor_name":"Hypercholesterolemia","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D007328","descriptor_name":"Insulin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D007333","descriptor_name":"Insulin Resistance","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008076","descriptor_name":"Cholesterol, HDL","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D008078","descriptor_name":"Cholesterol, LDL","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014280","descriptor_name":"Triglycerides","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D016022","descriptor_name":"Case-Control Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018149","descriptor_name":"Glucose Intolerance","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D018149","descriptor_name":"Glucose Intolerance","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D018149","descriptor_name":"Glucose Intolerance","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D024821","descriptor_name":"Metabolic Syndrome","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D024821","descriptor_name":"Metabolic Syndrome","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D024821","descriptor_name":"Metabolic Syndrome","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1111/dom.12788","doi":"https://doi.org/10.1111/dom.12788","is_oa":false,"landing_page_url":"https://doi.org/10.1111/dom.12788","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},{"id":"pmid:27619750","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/27619750","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, obesity & metabolism","raw_type":"Clinical Trial, Phase III"},{"id":"pmh:oai:ora.ox.ac.uk:uuid:526ef655-d0ae-4d23-87b4-2adad757c8d4","doi":null,"is_oa":false,"landing_page_url":"https://ora.ox.ac.uk/objects/uuid:526ef655-d0ae-4d23-87b4-2adad757c8d4/files/m6b1eaacfb5ddaa6a758f0bc1a1419418","pdf_url":null,"source":{"id":"https://openalex.org/S4306402636","display_name":"Oxford University Research Archive (ORA) (University of Oxford)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I40120149","host_organization_name":"University of Oxford","host_organization_lineage":["https://openalex.org/I40120149"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Symplectic Elements at Oxford","raw_type":"Journal article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"},{"id":"https://openalex.org/F4320309466","display_name":"Medpace","ror":"https://ror.org/05mgcmd27"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":37,"referenced_works":["https://openalex.org/W1433360308","https://openalex.org/W1520609538","https://openalex.org/W1962272706","https://openalex.org/W1972661406","https://openalex.org/W1990204315","https://openalex.org/W1997020689","https://openalex.org/W1998569580","https://openalex.org/W2001328643","https://openalex.org/W2004268446","https://openalex.org/W2006364971","https://openalex.org/W2041941938","https://openalex.org/W2052703897","https://openalex.org/W2054299101","https://openalex.org/W2069616685","https://openalex.org/W2085515275","https://openalex.org/W2093260782","https://openalex.org/W2098230963","https://openalex.org/W2103108681","https://openalex.org/W2103714496","https://openalex.org/W2107295258","https://openalex.org/W2115169717","https://openalex.org/W2134159541","https://openalex.org/W2137356728","https://openalex.org/W2141191772","https://openalex.org/W2147663252","https://openalex.org/W2151757154","https://openalex.org/W2155259933","https://openalex.org/W2160390128","https://openalex.org/W2165280863","https://openalex.org/W2169169620","https://openalex.org/W2194380546","https://openalex.org/W2210694332","https://openalex.org/W2216733834","https://openalex.org/W2219679120","https://openalex.org/W2266600614","https://openalex.org/W2477477042","https://openalex.org/W6906490681"],"related_works":["https://openalex.org/W2070668396","https://openalex.org/W2809611706","https://openalex.org/W2754562397","https://openalex.org/W2266600614","https://openalex.org/W2921986630","https://openalex.org/W2918318471","https://openalex.org/W4407046169","https://openalex.org/W2925864422","https://openalex.org/W2477477042","https://openalex.org/W2124565608"],"abstract_inverted_index":{"AIM:":[0],"To":[1],"examine":[2],"the":[3,198,246],"lipid":[4],"and":[5,105,128,172,190,202,212,220,242],"glycaemic":[6,67,235,247],"effects":[7,148],"of":[8,11,21,34,54,81,110,132,180,206],"52":[9,104,223],"weeks":[10,224],"treatment":[12],"with":[13,25,47,146,195,227],"evolocumab.":[14],"MATERIALS":[15],"AND":[16],"METHODS:":[17],"The":[18,92,177],"Durable":[19],"Effect":[20],"PCSK9":[22],"Antibody":[23],"Compared":[24],"Placebo":[26],"Study":[27],"(DESCARTES)":[28],"was":[29,90],"a":[30],"52-week":[31],"placebo-controlled":[32],"trial":[33],"evolocumab":[35,85,138,171,191],"that":[36],"randomized":[37],"905":[38],"patients":[39,62,112,226,244],"from":[40],"88":[41],"study":[42,55],"centres":[43],"in":[44,99,143,155,167,193,210,225,234],"9":[45],"countries,":[46],"901":[48],"receiving":[49],"at":[50,102,174,222],"least":[51],"one":[52],"dose":[53],"drug.":[56],"For":[57],"this":[58],"post-hoc":[59],"analysis,":[60],"DESCARTES":[61],"were":[63,96,165,200,208],"categorized":[64],"by":[65,141],"baseline":[66,196],"status:":[68],"type":[69,116],"2":[70,117],"diabetes,":[71],"impaired":[72],"fasting":[73,156],"glucose":[74],"(IFG),":[75],"metabolic":[76],"syndrome":[77],"(MetS)":[78],"or":[79,88,162,228,231],"none":[80,131],"these.":[82],"Monthly":[83],"subcutaneous":[84],"(420":[86],"mg)":[87],"placebo":[89,173,188],"administered.":[91],"main":[93],"outcomes":[94],"measured":[95],"percentage":[97],"change":[98],"LDL-cholesterol":[100],"(LDL-C)":[101],"week":[103,136,175],"safety.":[106],"RESULTS:":[107],"A":[108],"total":[109],"413":[111],"had":[113,122,126,130],"dysglycaemia":[114,230],"(120,":[115],"diabetes;":[118],"293,":[119],"IFG),":[120],"289":[121],"MetS":[123],"(194":[124],"also":[125],"IFG)":[127],"393":[129],"these":[133],"conditions.":[134],"At":[135],"52,":[137],"reduced":[139],"LDL-C":[140],">50%":[142],"all":[144],"subgroups,":[145],"favourable":[147],"on":[149],"other":[150],"lipids.":[151],"No":[152],"significant":[153],"differences":[154],"plasma":[157],"glucose,":[158],"HbA1c,":[159],"insulin,":[160],"C-peptide":[161],"HOMA":[163],"indices":[164],"seen":[166],"any":[168],"subgroup":[169],"between":[170,187,240],"52.":[176],"overall":[178],"incidence":[179],"new-onset":[181],"diabetes":[182],"mellitus":[183],"did":[184,237],"not":[185,238],"differ":[186,239],"(6.6%)":[189],"(5.6%);":[192],"those":[194],"normoglycaemia,":[197],"incidences":[199],"1.9%":[201],"2.7%,":[203],"respectively.":[204],"Incidences":[205],"AEs":[207],"similar":[209],"evolocumab-":[211,241],"placebo-treated":[213,243],"patients.":[214],"CONCLUSIONS:":[215],"Evolocumab":[216],"showed":[217],"encouraging":[218],"safety":[219],"efficacy":[221],"without":[229],"MetS.":[232],"Changes":[233],"parameters":[236],"within":[245],"subgroups":[248],"examined.":[249]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2522643247","counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":10},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":9},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":17},{"year":2017,"cited_by_count":11},{"year":2016,"cited_by_count":1}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-09-30T00:00:00"}
